NCT04815005 HoFH, the International Clinical Collaborators Registry
| NCT ID | NCT04815005 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Homozygous Familial Hypercholesterolemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2017-01-24 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2017-01-24 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of homozygous familial hypercholesterolemia (HoFH) clinically of genetically determined Exclusion Criteria: * No diagnosis of HoFH
Contact & Investigator
Marina Cuchel, MD, PhD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT04815005 clinical trial?
This trial is open to participants of all sexes, studying Homozygous Familial Hypercholesterolemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04815005 currently recruiting?
Yes, NCT04815005 is actively recruiting participants. Contact the research team at mcuchel@pennmedicine.upenn.edu for enrollment information.
Where is the NCT04815005 trial being conducted?
This trial is being conducted at Philadelphia, United States, Amsterdam, Netherlands, Cape Town, South Africa, Johannesburg, South Africa.
Who is sponsoring the NCT04815005 clinical trial?
NCT04815005 is sponsored by University of Pennsylvania. The principal investigator is Marina Cuchel, MD, PhD at University of Pennsylvania. The trial plans to enroll 1,000 participants.